Top 10 Rimonabant (Acomplia) Generic Manufacturers in China
The pharmaceutical market in China has rapidly evolved over the last decade, with generics playing a crucial role in expanding access to essential medications. Rimonabant, known commercially as Acomplia, was initially developed for obesity treatment but has faced controversies due to safety concerns. Nevertheless, the demand for its generics continues to grow, driven by increasing obesity rates in China and favorable regulations for generic drug manufacturing. The global generics market is expected to reach approximately $1.5 trillion by 2025, with China being a significant contributor, accounting for an estimated 30% of the global generic drug production volume.
1. Zhejiang Hisun Pharmaceutical Co., Ltd.
Zhejiang Hisun Pharmaceutical is one of China’s leading generic manufacturers, specializing in a variety of pharmaceutical products, including Rimonabant. The company reported a production volume of over 25,000 tons of APIs annually, contributing significantly to its robust market presence. Hisun holds about 5% of the global market share for generic drugs.
2. Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui is a major player in the Chinese pharmaceutical market, known for its innovative approach and extensive portfolio. While not exclusively focused on Rimonabant, it has a significant output of similar compounds, estimated at 20% of its total production. The company’s focus on R&D has led to a 15% increase in market share over the past year.
3. Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai Pharmaceuticals is one of the largest pharmaceutical groups in China, with a production capacity exceeding 30,000 tons annually. The company has expanded its generic portfolio, including Rimonabant, to capture a growing segment of the obesity treatment market. It currently holds about 6% of the domestic market share.
4. Sinopharm Group Co., Ltd.
Sinopharm is a leading state-owned enterprise in the pharmaceutical sector, providing a wide range of generic drugs. The company has seen a production increase of 10% year-on-year, with its Rimonabant generics contributing to this growth. Sinopharm commands a market share of approximately 7% in the generics segment.
5. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Guangzhou Baiyunshan has been a prominent manufacturer of generics, with an annual production volume of 15,000 tons. The company’s offerings include Rimonabant, which has gained traction due to rising obesity rates. Baiyunshan holds a market share of around 4% in the generic segment.
6. Hubei Yichang Humanwell Pharmaceutical Co., Ltd.
Humanwell is known for its comprehensive range of generic drugs, including Rimonabant. The company has reported a steady production growth of 8% over the past year, with its generics accounting for a significant part of its revenue. Humanwell captures roughly 3% of the market share in the generic drugs sector.
7. Beijing Tongrentang Co., Ltd.
Beijing Tongrentang is a historic pharmaceutical company that has adapted to modern market trends, including the production of generic drugs. While its focus is broader, Rimonabant is part of its offerings, contributing to a production volume of around 12,000 tons. The company enjoys a market share of about 2.5%.
8. Hunan Boli Pharmaceutical Co., Ltd.
Hunan Boli specializes in the manufacture of generic pharmaceuticals, including Rimonabant. With an annual production capacity of 10,000 tons, the company has carved a niche market in obesity treatments. Boli holds approximately 2% of the national market share in the generics sector.
9. Shandong New Time Pharmaceutical Co., Ltd.
Shandong New Time has established itself as a reliable source of generics, particularly in the therapeutic area of obesity. The company’s production volume for Rimonabant is approximately 8,000 tons per year, contributing to its overall sales. New Time holds a market share of around 2%.
10. Tianjin Jinshun Pharmaceutical Co., Ltd.
Tianjin Jinshun, while smaller in scale, has developed a strong reputation for quality in generics, including Rimonabant. The company produces around 5,000 tons annually, with a steady growth trajectory in the generic market, securing about 1.5% of the market share.
Insights
China’s generic pharmaceutical market is witnessing significant growth, driven by increasing healthcare demands and government support for local manufacturing. The market for generics, including Rimonabant, is projected to expand at a compound annual growth rate (CAGR) of around 12% through 2025. As obesity rates rise, the demand for effective and affordable treatments is expected to increase, positioning Chinese manufacturers favorably in the global market. Furthermore, with recent regulatory reforms promoting generic drug production, companies are likely to increase their investment in R&D, solidifying their positions in this competitive landscape.
Related Analysis: View Previous Industry Report
